Allergan - 500 Beiträge pro Seite

Kann mir bitte Jemand verständlich erklären, warum Allergan nicht weiter steigt ?
Die Produkte von denen sind zukunftsträchtig (die Nachfage steht) aber warum gehts nicht aufwärts?

Da muss ich mal rückfragen ob die Zahlen für 2016 schon da sind.

Also Ergebnis von 2016 wurde bereits veröffentlich, nun warten wir auf das erste Quartal 2017.

Hi, ich weiß nicht auf welchen Zeitraum du aus bist, aber technisch gesehen find ich die Aktie interessant. Solang der Bereich unter der 200 hält besteht meiner Meinung nach noch keine Gefahr. Es kommt vor dass ein Wert mal 50% oder mehr vom vorherigen Hoch korrigiert.
Beste Grüße!

Antwort auf yellowtrader 19.03.17 21:19:02 Uhr

na wie vor finde ich die Aktie interessant, insbesondere weil auch die Kundschaft immer abwechslungsreicher wird

http://www.spiegel.de/panorama/saudi-arabien-kamele-wegen-bo…

http://www.elastagen.com/allergan-to-acquire-elastagen-to-ac…


Allergan to Acquire Elastagen to Access Next Generation Injectable Portfolio

• Clinical stage tropoelastin platform with potential applications in aesthetics, scar remodeling and surgical wound repair
• Introduces key ‘youth protein’ tropoelastin to Allergan’s Juvederm dermal filler portfolio
• Provides infrastructure for further development and following approval to commercialize Elastagen’s products


SYDNEY February 7th:

Elastagen Pty Ltd, a clinical stage company developing medical device products based on recombinant tropoelastin, today announced that it has entered into a definitive agreement under which Allergan plc, a leading global biopharmaceutical company, has agreed to acquire Elastagen for an upfront payment of US$95M plus contingent, commercial payments.”

Elastagen’s revolutionary technology is based on recombinant human tropoelastin, the precursor of elastin which is a key component of youthful skin. Elastagen’s tropoelastin is identical to that present in human tissue, and has many potential clinical applications, including treatment for acne scars, stretch marks, aesthetic skin repair and surgical wound repair.

“Our Juvederm collection of fillers has sales of over $1 billion globally and is one of the fastest growing parts of our Aesthetics business,” said Bill Meury, Chief Commercial Officer at Allergan. “This acquisition and the development of a next generation of injectables based on this technology will ensure Allergan offers innovative filler products for years to come.”

Robert Daniels, Elastagen CEO, noted: “Partnering with Allergan, a leader in medical aesthetics, is incredibly exciting. I thank the Elastagen team for their hard work and dedication in developing our innovative tropoelastin product pipeline and look forward to working with Allergan to take these products to market.”

Commenting on the transaction, Elastagen’s founding scientist Prof Anthony Weiss added: “Our technology has come a long way from the lab bench at the University of Sydney towards developing products for patients around the world. I thank my team at the University of Sydney and greatly look forward to seeing our science commercialized by Allergan.”

Completion of the transition is subject to customary closing conditions, including review by Australia’s Foreign Investment Review Board.